New Drugs Get "Luck Of The Draw" In FDA's First Round Of 18-Month Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
"We're not being surprised by anything we are seeing" in the initial batch of FDAAA-mandated post-market assessments, FDA's Boucher says.